What's Happening

Stay up to date on pharmaceutical developments, industry issues, and what’s happening with Healthesystems

Events

Healthesystems’ conferences and speaking engagements

WCI Annual Conference

August 21-24, 2022 in Orlando Florida

Visit Healthe in booth #913 to learn more about our workers’ comp pharmacy & ancillary benefits

National Comp (NWCD Conference)

October 19-21, 2022 Las Vegas, Nevada

Visit Healthe in booth #621 to participate in our Annual Industry Survey for a chance to win $500

Attend our VP of Clinical Services, Dr. Silvia Sacalis’ session on Thursday 10/20 @ 2pm: “Building an Employee Culture of Well-Being and Trust Amid COVID and Beyond”

MedMonitor

An up-to-date timeline of FDA approvals that could impact workers' comp
View All MedMonitor Information

Leqembi (lecnemab-irmb) injection

Approval Date: Jan 2023

Note: New Product

Indicated for the treatment of Alzheimer’s in patients with mild cognitive impairment or mild dementia sage of the disease

hello world!

Sunlenca® (lenacapavir) tablets

Approval Date: Dec 2022

Note: New Product

In combination with other antiretrovirals, this drugs is indicated for treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection

hello world!

Idacio® (adalimumab-aacf) injection

Approval Date: Dec 2022

Note: New Product

Indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis

hello world!

Tzield® (teplizumab-mzwv) injection

Approval Date: Nov 2022

Note: New Product

A first-in-class medication, this drug is indicated to delay the onset of Stage 3 type 1 diabetes, potentially delaying the clinical diagnosis of type 1 diabetes to provide patients with months to years without the burdens of disease.

hello world!

Daliresp® (roflumilast) tablets

Approval Date: Sep 2022

Note: First-Time Generic

Indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations

hello world!

Tazorac® (tazarotene) gel

Approval Date: Sep 2022

Note: First-Time Generic

Indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement

hello world!

Byvalson (nebivolol and valsartan) tablets

Approval Date: Sep 2022

Note: First-Time Generic

Indicated for the treatment of hypertension, to lower blood pressure

hello world!

Prezista® (darunavir) tablets

Approval Date: Sep 2022

Note: First-Time Generic

Indicated for the treatment of HIV-1 infection

hello world!

Sotyktu (deucravacitnib) tablets

Approval Date: Sep 2022

Note: New Product

Indicated for the treatment of moderate-to-severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy

hello world!

Jardiance® (empagliflozin) tablets

Approval Date: Aug 2022

Note: First-Time Generic

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

hello world!
1 2 3 8

Social Hub

Check out our latest posts and activity
View All Social Media
    lockenvelopephone-handsetmenucross-circle